Millipore Sigma Vibrant Logo

204881 Complement C3a, Human

204881
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
204881-50UG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Ampoule plast. 50 μg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewNative, human C3a complement component. Single chain, 77 amino acid peptide. Activation of either complement pathway can result in formation of C3-cleaving enzymes (C3 convertases) on target surfaces. The C3 convertase enzymes of either complement activation pathway will cleave the C3 α-chain at peptide bond 77 resulting in the production and release of the C3a peptide. C3a, one of the three complement-derived anaphylatoxins, expresses a wide variety of biological activities which include smooth muscle contraction, platelet and neutrophil activation and aggregation, skin wheal and flare, and immunoregulatory reactions.
      Catalogue Number204881
      Brand Family Calbiochem®
      References
      ReferencesHugli, T.E. 1989. Curr. Top. Micro. Immunol. 153, 181.
      Hugli, T.E. 1986. Complement 3, 111.
      Product Information
      FormLiquid
      FormulationIn PBS, pH 7.2, sterile-filtered through a 0.22 µm filter.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      ContaminantsC3adesArg; ≤10%
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Complement C3a, Human FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Complement C3a, Human Certificats d'analyse

      TitreNuméro de lot
      204881

      Références bibliographiques

      Aperçu de la référence bibliographique
      Hugli, T.E. 1989. Curr. Top. Micro. Immunol. 153, 181.
      Hugli, T.E. 1986. Complement 3, 111.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-May-2008 RFH
      DescriptionNative, human C3a complement component. Single chain, 77 amino acid peptide. Activation of either complement pathway can result in formation of C3-cleaving enzyme (C3 convertases) on target surfaces. The C3 convertase enzymes of either complement activation pathway will cleave the C3 α-chain at peptide bond 77, resulting in the production and release of the C3a peptide. C3a, one of the three complement-derived anaphylatoxins, expresses a wide variety of biological activities, which include smooth muscle contraction, platelet and neutrophil activation and aggregation, skin wheal and flare, and immunoregulatory reactions.
      FormLiquid
      FormulationIn PBS, pH 7.2, sterile-filtered through a 0.22 µm filter.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Purity≥95% by SDS-PAGE
      ContaminantsC3adesArg; ≤10%
      Storage ≤ -70°C
      Avoid freeze/thaw
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesHugli, T.E. 1989. Curr. Top. Micro. Immunol. 153, 181.
      Hugli, T.E. 1986. Complement 3, 111.